<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Startups on Nimverta</title>
    <link>http://localhost:1313/New_hugo/tags/startups/</link>
    <description>Recent content in Startups on Nimverta</description>
    <generator>Hugo</generator>
    <language>en-us</language>
    <lastBuildDate>Tue, 24 Jun 2025 09:00:00 +0200</lastBuildDate>
    <atom:link href="http://localhost:1313/New_hugo/tags/startups/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>Nimverta Secures Venture Kick Support to Advance Bone Regeneration Therapy</title>
      <link>http://localhost:1313/New_hugo/blog/simple-blog-post-1/</link>
      <pubDate>Tue, 24 Jun 2025 09:00:00 +0200</pubDate>
      <guid>http://localhost:1313/New_hugo/blog/simple-blog-post-1/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Nimverta&lt;/strong&gt;, a Zurich-based biotech startup, has secured CHF 10,000 in funding from &lt;a href=&#34;https://www.venturekick.ch&#34;&gt;Venture Kick&lt;/a&gt;, entering a new phase in its journey to develop first-in-class peptide therapies for bone regeneration. The support is part of &lt;a href=&#34;https://www.venturekick.ch/CHF-10000-for-firstinclass-peptide-therapeutics-E-coli-vaccine-cold-chain-logistics-a-software-for-diplomats-and-therapies-for-bone-disease&#34;&gt;Venture Kickâ€™s Stage I&lt;/a&gt;, designed to catalyze high-potential Swiss startups.&lt;/p&gt;</description>
    </item>
  </channel>
</rss>
